Company Profile
Tyra Biosciences Stock Price, News & Analysis
- Ticker:
- TYRA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
31.06 USD (+1.40%)
Close
Last updated: July 27, 2026
1.7B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, TYRA closed up 1.40% at $31.06. No new same-company headline was identified in the current news window.
Company overview
Business overview
Tyra Biosciences is a precision-oncology company focused on FGFR and related kinase biology. The company is trying to build a targeted-therapy franchise around genetically defined cancers.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Tyra sits in specialty oncology biotechnology.
Business Model Characteristics
The company depends on clinical proof, molecule selectivity, and the possibility of creating a differentiated kinase platform.
Position Within the Biotechnology Landscape
Tyra is a high-beta oncology name whose valuation is highly sensitive to early clinical data.
Future catalysts
Tyra Biosciences's catalyst is TYRA-300, with FGFR3-driven bladder-cancer data and related FGFR updates likely to matter most. The market will care about whether the precision-oncology story stays differentiated.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Tyra Biosciences (TYRA)?
Tyra Biosciences (TYRA) most recently closed at 31.06 USD, a +1.40% move versus the previous session.
What is the market cap of Tyra Biosciences (TYRA)?
Tyra Biosciences currently has a market capitalization of 1.7B USD on BioPharmSignal.
What does Tyra Biosciences do?
Tyra Biosciences is a precision-oncology company focused on FGFR and related kinase biology. The company is trying to build a targeted-therapy franchise around genetically defined cancers.
On which exchange is TYRA stock listed?
Tyra Biosciences (TYRA) is associated with NASDAQ, United States, Biopharma.
What is TYRA-300?
Tyra Biosciences's catalyst is TYRA-300, with FGFR3-driven bladder-cancer data and related FGFR updates likely to matter most.
Which conditions is Tyra Biosciences targeting with TYRA-300?
Tyra Biosciences is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does Tyra Biosciences describe recent progress with TYRA-300?
Tyra Biosciences's catalyst is TYRA-300, with FGFR3-driven bladder-cancer data and related FGFR updates likely to matter most.
What is Tyra?
Tyra Biosciences is a precision-oncology company focused on FGFR and related kinase biology.